Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].
Michele Bottosso, Renata L Sandoval, Benjamin Verret, Natalia Polidorio, Olivier Caron, Alessandra Gennari, Brittany L Bychkovsky, Sophie H Cahill, Maria I Achatz, Valentina Guarneri, Fabrice Andr��, Judy E Garber
Author Information
- Michele Bottosso: INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy. Electronic address: michele.bottosso@iov.veneto.it.
- Renata L Sandoval: Medical Oncology Center, Hospital S��rio-Liban��s, Bras��lia, DF, Brazil.
- Benjamin Verret: INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France.
- Natalia Polidorio: Breast Surgery Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Olivier Caron: Gustave Roussy, D��partement de m��decine oncologique, Villejuif F-94805, France.
- Alessandra Gennari: Department of Translational Medicine, University of Piemonte Orientale (UPO), Novara, Italy; Medical Oncology, "Maggiore Della Carit��" University Hospital, Novara, Italy.
- Brittany L Bychkovsky: Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
- Sophie H Cahill: Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
- Maria I Achatz: Centro de Oncologia, Hospital S��rio-Liban��s, Sao Paulo, SP, Brazil.
- Valentina Guarneri: Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy.
- Fabrice Andr��: INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; PRISM, INSERM, Gustave Roussy, Villejuif, France; Paris Saclay University, Gif Sur-Yvette, France.
- Judy E Garber: Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
No abstract text available.
